Trevi Therapeutics, Inc.
TRVI- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001563880
In the last 90 days, Trevi Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 218 institutions reported holding it in 13F filings for Q2 2026, worth $2.76B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $595.8K in total
- 1
- 13F holdersQ2 2026, +22 vs. previous quarter
- 218
- 13F valueReported value at the end of Q2 2026
- $2.76B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding TRVI, Q2 2026
1 superinvestor reports holding Trevi Therapeutics, Inc. on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
0.1%
Trevi Therapeutics, Inc.'s share of the portfolio
- Shares
- 1,544,644
- Value
- $28.8M
Latest insider trades
Open-market purchases and sales by Trevi Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:55 PM ET | Sep 15 | 2 days | Heffernan Michael ThomasDirector | SSale | −39.5K | $15.09 | −$595.8K | −86.1%6.35K after | 4 lots10b5-1 |
| Mar 26, 2025 (view filing) | Mar 25 | 1 day | Sciascia ThomasChief Scientific Officer | SSale | −2.63K | $6.60 | −$17.4K | −1.2%221.4K after | |
| Mar 25, 2025 (view filing) | Mar 21 | 4 days | Good Jennifer LPresident & CEO | SSale | −5.26K | $6.58 | −$34.6K | −2.4%213.3K after | |
| Mar 12, 2025 (view filing) | Mar 10 | 2 days | Simon FarrellChief Commercial Officer | SSale | −81.3K | $6.75 | −$549.1K | −51.4%76.9K after | 2 lots10b5-1 |
| Sep 9, 2024 (view filing) | Sep 6-9 | 3 days | Good Jennifer LPresident & CEO | SSale | −6.06K | $3.03 | −$18.4K | −2.8%213.3K after | 2 lots |
| Sep 5, 2024 (view filing) | Sep 3-5 | 2 days | Good Jennifer LPresident & CEO | SSale | −55.1K | $3.09 | −$170.1K | −20.5%213.3K after | 3 lots |
| Aug 29, 2024 (view filing) | Aug 27 | 2 days | Meeker David PDirector | SSale | −4.55K | $2.93 | −$13.3K | −1.3%352.5K after | |
| Aug 21, 2024 (view filing) | Aug 19 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −16.5K | $2.96 | −$48.8K | −7.0%220.3K after | |
| Aug 16, 2024 (view filing) | Aug 14-16 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −31.5K | $2.77 | −$87.3K | −12.5%220.3K after | 3 lots |
| May 31, 2024 (view filing) | May 29 | 2 days | Sciascia ThomasChief Scientific Officer | SSale | −53.4K | $2.55 | −$136.1K | −19.9%214.4K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in Trevi Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| NEA Management Company, LLC | 13,222,228 | $246.6M | 15.53% | 00.0% | Unchanged |
| FMR LLC | 12,562,839 | $234.3M | 0.01% | +4,524,778+56.3% | Added |
| BlackRock, Inc. | 11,155,026 | $208.0M | 0.00% | +914,840+8.9% | Added |
| Frazier Life Sciences Management, L.P. | 9,939,447 | $185.4M | 4.04% | −1000.0% | Reduced |
| Wellington Management Group LLP | 5,684,592 | $106.0M | 0.02% | +495,504+9.5% | Added |
| Vanguard Capital Management LLC | 5,530,675 | $103.1M | 0.00% | +552,108+11.1% | Added |
| Vivo Capital, LLC | 5,094,668 | $95.0M | 8.68% | 00.0% | Unchanged |
| Woodline Partners LP | 4,081,333 | $76.1M | 0.24% | +3,080,551+307.8% | Added |
| Vestal Point Capital, LP | 3,100,000 | $57.8M | 1.35% | +933,496+43.1% | Added |
| MPM Oncology Impact Management LP | 3,073,577 | $57.3M | 3.50% | −224,853−6.8% | Reduced |